Innate Immunotherapeutics Limited (ASX Code:IIL) has today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 September 2016.
The cash balance as at 30 September 2016 was $7,777,000, an increase of $6,753,000 from the end of the previous quarter.
Net cash usage for the three months was $177,000 following receipt of a R&D tax incentive payment of $1,824,000. Payments during the period included $1,006,000 related to research and development, being principally the Company's Phase 2B trial of MIS416 in patients with secondary progressive multiple sclerosis (SPMS). The last patient in this trial is expected to complete all study related visits in early May and the clinical study report is expected about four months later.
For further information please download PDF attached:
Download this document
